Neoplasms, Glandular and Epithelial
Information
- Disease name
- Neoplasms, Glandular and Epithelial
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03911388 | Active, not recruiting | Phase 1 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | September 12, 2019 | September 1, 2026 |
| NCT05592743 | Available | Vorasidenib Expanded Access Program | |||
| NCT00325130 | Completed | Phase 3 | Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) | April 2006 | April 2007 |
| NCT00337428 | Completed | Phase 3 | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) | May 2006 | May 2007 |
| NCT02897778 | Completed | Phase 1 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | August 24, 2016 | March 13, 2017 |
| NCT02909452 | Completed | Phase 1 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | September 20, 2016 | February 9, 2021 |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT03072472 | Completed | N/A | BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities | February 14, 2017 | February 13, 2018 |
| NCT03562897 | Completed | Phase 2 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | October 25, 2018 | June 15, 2022 |
| NCT04008082 | Completed | A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma | May 14, 2019 | January 28, 2022 | |
| NCT04807166 | Not yet recruiting | Phase 2 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | June 1, 2021 | December 1, 2024 |
| NCT05797246 | Recruiting | Phase 2 | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) | August 2, 2023 | November 2, 2026 |
| NCT05152927 | Recruiting | N/A | Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy | January 10, 2022 | January 31, 2025 |
| NCT05935748 | Recruiting | Phase 2 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | July 28, 2023 | September 2026 |
| NCT04124198 | Recruiting | N/A | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | March 1, 2019 | January 2029 |
| NCT04519151 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | April 12, 2021 | November 2029 |
| NCT05617755 | Recruiting | Phase 1 | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | November 29, 2022 | February 2027 |
| NCT00481936 | Terminated | Phase 1 | Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | May 2007 | April 2008 |
| NCT01234480 | Terminated | Intended Use Study of the BD SurePath Plus™ Pap | September 2010 | August 2012 | |
| NCT00672009 | Terminated | Phase 2 | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | April 2008 | August 2012 |
| NCT01009593 | Terminated | Phase 3 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | January 2010 | July 2012 |
| NCT02005965 | Unknown status | Low Rectal Cancer Study (MERCURY II) | August 13, 2007 | March 11, 2021 | |
| NCT04556071 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | November 6, 2020 | October 1, 2022 |
| NCT04566952 | Unknown status | Phase 2 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | October 28, 2020 | October 1, 2023 |
| NCT01037049 | Unknown status | Phase 2 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | October 16, 2009 | December 8, 2019 |
| NCT01556815 | Unknown status | Phase 2 | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma | May 2012 | May 2015 |
| NCT01995942 | Unknown status | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | June 7, 2013 | February 2, 2022 | |
| NCT02192671 | Unknown status | Phase 3 | HR Versus RFA for HCC in Patients With PHT | May 2015 | December 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009375